Phase 2 N=47 Safety and Efficacy of a Drug Delivery System in Glaucoma
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change in Intraocular Pressure at Day 1 — -4.16; -4.57; -0.60 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=121 Glaucoma Biomarkers
Glaucoma · Healthy
Primary: Variation in Eye Pressure Between Individuals. — 11.5; 11.3; 11.0; 11.0 mmHg — p=0.0001
Phase 4 N=35 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Glaucoma; Drugs · Normal Tension Glaucoma · Primary Open-angle Glaucoma
Primary: Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography — -0.51; 2.59; -0.96; 0.96 percent change
Phase 2 N=55 Safety and Efficacy of a Glaucoma Drug Delivery System
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Visual Acuity - Right Eye — 0.015; -0.044; -0.012 logMAR units
Phase 2 N=123 Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 24.1; 23.6; 13.9; 16.9 mmHg — p=0.001
Phase 2 N=55 A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) on Day 8 — 17.83; 19.15; 19.59; 17.51 mm Hg
Phase 4 N=97 Steroids After Laser Trabeculoplasty for Glaucoma
Glaucoma
Primary: Intraocular Pressure (IOP) Change — -3.0; -6.2; -5.2 mmHg
Phase 3 N=148 DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Open Angle Glaucoma or Ocular Hypertension
Primary: Change From Baseline in IOP (Intraocular Pressure) at End of Study — -1.8 mmHg
Phase 2 N=67 Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
Primary Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I — 25.97; 26.25; 25.90; 26.44 mmHg — p=0.028
Phase 3 N=52 Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration · Wet Macular Degeneration
Primary: Change in Mean Central Subfield Thickness (CST) — -36.6; 1.7 microns — p=0.04
Phase 2 N=226 Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure Over 84 Days — 22.0; 22.5; 18.8; 19.4 mmHg
N/A N=21 The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble
Scleral Buckling
Primary: Complete Resolution of Intraocular Gas Bubble — 40.4; 37.8 Duration in days, gas bubble
Phase 2 N=201 Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
Primary Open-Angle Glaucoma (POAG) · Ocular Hypertension (OHT)
Primary: Mean Intraocular Pressure (IOP) — -6.4; -6.8; -6.4; -7.1 mm of mercury
Phase 2 N=37 COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)
Glaucoma
Primary: Mean Change in the Peak Intraocular Pressure (IOP) Measured Two Hours After Study Drug Administration at Week 12 Compared to Baseline IOP. — -3.73 mmHg — p=<0.0001
Phase 2 N=10 A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Exfoliation Syndrome · Ocular Hypertension · Open Angle Glaucoma
Primary: Evaluate the Ocular Hypotensive Efficacy of Rho Kinase Inhibitor (AR-12286 0.5% and 0.7%) — 24.2; 25.8 mmHg
N/A N=56 Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data
Glaucoma
Primary: 6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV) — 2.32; -.30 cm/sec — p=.6261
Phase 4 N=52 Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma
Glaucoma
Primary: Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma — 9; 12 participants
N/A N=16 Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Primary Open Angle Glaucoma
Primary: Blood Oxygenation — 60; 60; 60 percentage of oxygenation
Phase 2 N=37 Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma
Childhood Glaucoma
Primary: Percentage of Eyes With Response — 33 eyes
Phase 4 N=376 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 25.4; -6.3 Millimeters of Mercury (mmHg)
Phase 3 N=888 Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Diurnal IOP Change From Baseline at Month 3 — -8.5; -8.3 millimeters of mercury (mmHg)
N/A N=1,553 A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.18; 16.11 mmHg
Phase 3 N=560 Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Diurnal IOP Change From Baseline at Month 3 — -7.9; -6.5; -6.4 millimeters of mercury (mmHg)
Phase 2 N=201 Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Glaucoma Open-Angle Primary · Ocular Hypertension
Primary: Efficacy as Assessed by Change in Intraocular Pressure — -6.3; -6.3; -5.9; -7.0 mmHg
N/A N=392 GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) — 22.0; -6.0; 22.0; -6.0 Millimeters of Mercury (mmHg)
Phase 2 N=109 Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Time-Matched Intraocular Pressure (IOP) in the Study Eye — 26.57; 25.14; 24.48; 25.14 Millimeters of Mercury (mmHg)
Phase 2 N=112 A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP) — 24.54; 24.38; 24.29; -6.79 Millimeters of Mercury (mmHg)
N/A N=7 Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
Glaucoma
Primary: Presence of Retinal Vascular Dysregulation (RVD) — 7; 4 Participants
Phase 4 N=263 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) in the Study Eye — 16.5; 16.7; 15.7; 16.1 Millimeters of Mercury (mmHg)
Phase 4 N=111 Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
Glaucoma
Primary: Mean Intraocular Pressure (IOP) at 9 AM — 16.3; 18.1 millimeters mercury (mmHg)